If you've been following science news in recent years, or even months, you know there have been new discoveries about the biological drivers of prostate cancer. And diagnostics companies have been jockeying to address the huge market that awaits them with tests that they hope provide valuable information to guide the treatment of men with the disease.
It can be a tricky to keep up with all the firms in pursuit of new prostate cancer tests--including Genomic Health, Myriad Genetics, and several smaller firms--so we've compiled a roundup of five developers to keep on your radar. These companies are not meant to be the top five in the field, but they are certainly meant to be representative of the new prostate cancer diagnostics under development to address a range of questions about how to best treat the disease. Read the report >>